Figure and Table | Availability of Serum Levels of Carbohydrate Antigen 19-9 (CA19-9) as a Surrogate Tumor Marker for Papillary Thyroid Carcinoma

Table 1. Clinicopathological Characteristics of Patients with PTC with Normal and High Serum CA19-9 Levels before Surgery.

	Normal serum CA19-9	High serum CA19-9	p-value
No. of patients	184 (93.9%)	12 (6.1%)
Age, years ^a	47 (16-89)	38.5 (18-87)	0.531
Gender:
Male	45 (24.5%)	3 (25.0%)	0.975
Female	139 (75.5%)	9 (75.0%)
Max. tumor size, mm ^a	26 (20-110)	33 (20-61)	0.130
Anti-thyroglobulin antibody:
Positive	32	1	0.695
Negative	152	11
Serum thyroglobulin levels before surgery, ng/mL^a,b	59.8 (2.0-2684)	122.0 (1.0-1875)	0.400
Serum thyroglobulin levels after surgery, ng/mL^a,b	1.2 (0.1-185)	2.3 (0.3-377.7)	0.308
Extrathyroidal invasion:
Positive	10	2	0.287
Negative	174	10
Nodal metastasis:
Positive	159	11	0.249
Negative	25	1
Vascular invasion:
Positive	10	1	0.512
Negative	174	11
Lymphangial invasion:
Positive	4	2	0.046
Negative	180	10
Ki-67 labeling index:
0%-5%	119	8
5%-10%	37	2	0.567
>10%	5	1
Unknown	23	1
Serum level of CA19-9, U/mL: ^a
Before surgery	11.2 (1-36.3)	60.5 (40.8-221)	<0.01
After surgery	9.0 (1-29.5)	32.5 (17.5-36)	<0.01

Table 2. Relationship between Serum CA19-9 Levels and CA19-9 Immunostaining Results.